The squamous cell carcinoma market reached a value of USD 739.1 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 1,469.0 Million by 2035, exhibiting a growth rate (CAGR) of 6.43% during 2025-2035.
Report Attribute
|
Key Statistics
|
---|---|
Base Year |
2024
|
Forecast Years | 2025-2035 |
Historical Years |
2019-2024
|
Market Size in 2024
|
USD 739.1 Million |
Market Forecast in 2035
|
USD 1,469.0 Million |
Market Growth Rate 2025-2035 | 6.43% |
The squamous cell carcinoma market has been comprehensively analyzed in IMARC's new report titled "Squamous Cell Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Squamous cell carcinoma refers to a type of cancer that occurs in the squamous cells, which are thin, flat cells that form the skin's surface, the lining of the hollow organs, and the respiratory as well as digestive tracts. This disease typically develops in areas exposed to the sun, such as the head, hands, neck, and lower legs, but it can also appear in other parts of the body. The most common symptom of the ailment is a scaly patch or a firm, red bump on the skin. Individuals suffering from this illness might also experience persistent soreness that may be painful, tender, or itchy; thickened, raised, or hardened skin regions; swollen lymph nodes; difficulty swallowing; changes in voice; etc. The diagnosis of squamous cell carcinoma involves a medical history assessment, a physical examination, and a biopsy. A healthcare professional will initially examine the affected area and check for any suspicious growths, sores, or changes in the skin's appearance. In some cases, various imaging studies, such as X-rays, CT scans, MRIs, etc., are also performed to detect the extent of the tumor and identify any metastases.
The increasing cases of prolonged exposure to ultraviolet (UV) radiation from tanning beds or the sun, which can lead to genetic mutations in the cellular DNA, are primarily driving the squamous cell carcinoma market. In addition to this, the rising incidences of several associated risk factors, including chronic wounds or inflammation, advancing age, a weakened immune system, etc., are further bolstering the market growth. Moreover, the widespread adoption of effective topical therapeutic agents, such as 5-fluorouracil and imiquimod, that can be directly applied to the affected site for disrupting cancerous cells is also acting as a significant growth-inducing factor. Besides this, the escalating utilization of cryotherapy, since it involves freezing the tumor with liquid nitrogen, thereby preventing the progression of the illness, is further creating a positive outlook for the market. Additionally, the emerging popularity of Mohs micrographic surgery to treat advanced and recurrent disease conditions, owing to its various advantages, like precise tumor mapping and high cure rates with minimal damage to the surrounding healthy tissue, is expected to drive the squamous cell carcinoma market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the squamous cell carcinoma market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for squamous cell carcinoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the squamous cell carcinoma market in any manner.
Libtayo (Cemiplimab) is a fully human monoclonal antibody that targets the immunological checkpoint receptor PD-1 on T cells, developed utilizing Regeneron’s unique velocimmune technology. Libtayo has been demonstrated to inhibit cancer cells from suppressing T-cell activation by binding to PD-1. In the United States and other countries, Libtayo is indicated in select individuals with advanced basal cell carcinoma and advanced cutaneous squamous cell carcinoma.
PRV-111 is an investigational drug currently being explored for the treatment of oral Squamous Cell Carcinoma (SCC). It is a novel compound designed to target specific molecular pathways involved in tumor growth and progression, offering potential benefits in treating advanced or resistant SCC. Clinical studies are ongoing to assess its efficacy and safety in SCC patients.
Time Period of the Study
Countries Covered
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current squamous cell carcinoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Late-Stage Pipeline Drugs
Drugs | Company Name |
---|---|
Libtayo (Cemiplimab) | Regeneron Pharmaceuticals |
Opdivo (Nivolumab) | Bristol-Myers Squibb |
PRV 111 | Privo Technologies |
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Market Insights
Epidemiology Insights
Squamous Cell Carcinoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies